Patent ID: 8492358

Claim:
A synthetic TLR3 agonist comprising i) a first oligoribonucleotide having the structure: 5′-Domain A-Domain B-3′; and ii) a second oligoribonucleotide having the structure: 5′-Domain C-Domain D-3′, wherein Domain A is a first complementary domain, Domain B is a polyriboinosine domain, Domain C is a second complementary domain and Domain D is a polyribocytidine domain, wherein Domain A and Domain C are complementary to each other, are from about 10 to about 20 nucleotides in length, and comprise G, C, A, T and/or U, wherein the first oligoribonucleotide and the second oligoribonucleotide bind to each other through intermolecular hydrogen bonding between (i) the complementary domains leaving a free polyriboinosine domain and a free polyribocytidine domain or (ii) between the polyriboinosine and polyribocytidine domains leaving a free first complementary domain and a free second complementary domain, and wherein additional first and/or second oligoribonucleotides can bind to the free complementary and/or polyriboinosine or polyribocytidine domains, thereby creating a chain of oligoribonucleotides.